DHT/Dihydrotestosterone/Stanolone CAS 521-18-6 a sex steroid and androgen hormone
Stanolone
Chemical Name:androstanolone (5α-androstan-17β-ol-3-one) ,17β-hydroxy-5α-androstan-3-one
CAS No.: 521-18-6
MF: C19H30O2
Appearance: white crystalline powder
Usage:The enzyme 5α-reductase synthesizes DHT in the prostate, testes, hair follicles, and adrenal glands. This enzyme reduces the 4,5 double-bond of the hormone testosterone.
Effects on sexual development:
In men, approximately 5% of testosterone undergoes 5α-reduction to form the more potent androgen, dihydrotestosterone (DHT). DHT has two to three times greater androgen receptor affinity than testosterone and has 15-30 times greater affinity than adrenal androgens. The dissociation rate of testosterone from the receptor is five-fold faster than DHT.During embryogenesis DHT has an essential role in the formation of the male external genitalia, while in the adult DHT acts as the primary androgen in the prostate and in hair follicles.
An example illustrating the significance of DHT for the development of secondary sex characteristics is congenital 5-α-reductase (5-AR) deficiency. This gene lesion can result in pseudohermaphroditism. This condition typically presents with underdeveloped male genitalia and prostate. These individuals are often raised as girls due to their lack of conspicuous male genitalia.In the onset of puberty, although their DHT levels remain very low, their testosterone levels elevate normally. Their musculature develops like that of other male adults. After puberty, men with this condition have a large deficiency of pubic and body hair, and no incidence of male pattern baldness.
Unlike other androgens such as testosterone, DHT cannot be converted by the enzyme aromatase to estradiol. Therefore, it is frequently used in research settings to distinguish between the effects of testosterone caused by binding to the androgen receptor and those caused by testosterone's conversion to estradiol and subsequent binding to estrogen receptors
Pathology:
DHT is the primary contributing factor in male pattern baldness that results from hair follicle miniaturisation. However, female hair loss is more complex, and DHT is only one of several possible causes.Women with increased levels of DHT may develop certain androgynous male secondary sex characteristics, including a deepened voice and facial hair. DHT plays a role in the development and exacerbation of benign prostatic hyperplasia, as well as prostate cancer, by enlarging the prostate gland.Prostate growth and differentiation are highly dependent on sex steroid hormones, particularly DHT
Treatment:
5α-reductase inhibitors are commonly used for the treatment of two DHT-related conditions, male pattern baldness (MPB), and benign prostatic hyperplasia (BPH). Dutasteride is approved for the treatment of benign prostatic hyperplasia, and is prescribed off-label for the treatment of male pattern baldness, whereas finasteride is approved for both conditions. Dutasteride is three times more potent than finasteride in inhibiting the type II enzyme and 100 times more potent than finasteride in inhibiting the type I form of the DHT-producing enzyme. Both finasteride and dutasteride are potent inhibitors of the third isotype of the enzyme.
However, 5α-reductase inhibitors are thought to have persistent side effects that can continue after quitting the treatment, including diminished libido, erectile dysfunction and male breast cancer,and are suspected to have persistent cognitive side effects, including depression,brain fog and memory loss
Permanent link: http://www.vvchem.com/sell/cas:521-18-6,3309068.html
China
